Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

View More View Less
  • 1 Fox Chase Cancer Center;
  • | 2 Roswell Park Comprehensive Cancer Center;
  • | 3 City of Hope National Medical Center;
  • | 4 Moffitt Cancer Center;
  • | 5 UC Davis Comprehensive Cancer Center;
  • | 6 Massachusetts General Hospital Cancer Center;
  • | 7 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • | 8 UCLA Jonsson Comprehensive Cancer Center;
  • | 9 Stanford Cancer Institute;
  • | 10 O'Neal Comprehensive Cancer Center at UAB;
  • | 11 UT Southwestern Simmons Comprehensive Cancer Center;
  • | 12 Vanderbilt-Ingram Cancer Center;
  • | 13 Memorial Sloan Kettering Cancer Center;
  • | 14 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;
  • | 15 University of Colorado Cancer Center;
  • | 16 Fred & Pamela Buffett Cancer Center;
  • | 17 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • | 18 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • | 19 St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;
  • | 20 University of Wisconsin Carbone Cancer Center;
  • | 21 Mayo Clinic Cancer Center;
  • | 22 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • | 23 Huntsman Cancer Institute at the University of Utah;
  • | 24 Duke Cancer Institute;
  • | 25 University of Michigan Rogel Cancer Center;
  • | 26 Abramson Cancer Center at the University of Pennsylvania;
  • | 27 UC San Diego Moores Cancer Center;
  • | 28 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;
  • | 29 UCSF Helen Diller Family Comprehensive Cancer Center; and
  • | 30 National Comprehensive Cancer Network.

Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.

Individual Disclosures for the NCCN Soft Tissue Sarcoma Panel
Individual Disclosures for the NCCN Soft Tissue Sarcoma Panel

  • 1.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:733.

  • 2.

    Brady MS, Gaynor JJ, Brennan MF. Radiation-associated sarcoma of bone and soft tissue. Arch Surg 1992;127:13791385.

  • 3.

    Zahm SH, Fraumeni JF Jr. The epidemiology of soft tissue sarcoma. Semin Oncol 1997;24:504514.

  • 4.

    Penel N, Grosjean J, Robin YM, et al. Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases. Sarcoma 2008;2008:459386.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    American Cancer Society. Risk factors for soft tissue sarcomas. Accessed April 12, 2022. Available at: https://www.cancer.org/cancer/soft-tissue-sarcoma/causes-risks-prevention/risk-factors.html

    • Search Google Scholar
    • Export Citation
  • 6.

    Pisters PWT, Weiss M, Maki R. Soft-tissue sarcomas. In Haller DG, Wagman LD, Camphausen C, et al., eds. Cancer Management:A Multidisciplinary Approach Medical, Surgical, & Radiation Oncology. 14th ed. UBM Medica LLC; 2011.

    • Search Google Scholar
    • Export Citation
  • 7.

    Clasby R, Tilling K, Smith MA, et al. Variable management of soft tissue sarcoma: regional audit with implications for specialist care. Br J Surg 1997;84:16921696.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Voss RK, Chiang YJ, Torres KE, et al. Adherence to National Comprehensive Cancer Network Guidelines is associated with improved survival for patients with stage 2A and stages 2B and 3 extremity and superficial trunk soft tissue sarcoma. Ann Surg Oncol 2017;24:32713278.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Musat E, Kantor G, Caron J, et al. Étude théorique d'une radiothérapie postopératoire avec modulation d'intensité d'un sarcome rétropéritonéal [Comparison of intensity-modulated postoperative radiotherapy with conventional postoperative conformal radiotherapy for retroperitoneal sarcoma]. Cancer Radiother 2004;8:255261 [in French].

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Yoon SS, Chen YL, Kirsch DG, et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. Ann Surg Oncol 2010;17:15151529.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Kim B, Chen YL, Kirsch DG, et al. An effective preoperative three- dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Oncol Biol Phys 2010;77:843850.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Swanson EL, Indelicato DJ, Louis D, et al. Comparison of three-dimensional (3D) conformal proton radiotherapy (RT), 3D conformal photon RT, and intensity-modulated RT for retroperitoneal and intra-abdominal sarcomas. Int J Radiat Oncol Biol Phys 2012;83:15491557.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Trans-Atlantic RPS Working Group. Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol 2015;22:256263.

    • Search Google Scholar
    • Export Citation
  • 14.

    Zlotecki RA, Katz TS, Morris CG, et al. Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma: the University of Florida experience. Am J Clin Oncol 2005;28:310316.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Baldini EH, Wang D, Haas RLM, et al. Treatment guidelines for preoperative radiation therapy for retroperitoneal sarcoma: preliminary consensus of an international expert panel. Int J Radiat Oncol Biol Phys 2015;92:602612.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Albertsmeier M, Rauch A, Roeder F, et al. External beam radiation therapy for resectable soft tissue sarcoma: a systematic review and meta-analysis. Ann Surg Oncol 2018;25:754767.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Pawlik TM, Pisters PWT, Mikula L, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol 2006;13:508517.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2020;21:13661377.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Chowdhary M, Spraker MB. Preoperative radiotherapy for retroperitoneal sarcoma. Lancet Oncol 2021;22:e2.

  • 20.

    DeLaney T, Mullen JT, Wang D, et al. Preoperative radiotherapy for retroperitoneal sarcoma. Lancet Oncol 2021;22:e1.

  • 21.

    Izzuddeen Y, Sharma DN. Preoperative radiotherapy for retroperitoneal sarcoma. Lancet Oncol 2021;22:e3.

  • 22.

    Baldini EH, Bosch W, Kane JM III, et al. Retroperitoneal sarcoma (RPS) high risk gross tumor volume boost (HR GTV boost) contour delineation agreement among NRG sarcoma radiation and surgical oncologists. Ann Surg Oncol 2015;22:28462852.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Tzeng CWD, Fiveash JB, Popple RA, et al. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. Cancer 2006;107:371379.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Sindelar WF, Kinsella TJ, Chen PW, et al. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. Arch Surg 1993;128:402410.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Alektiar KM, Hu K, Anderson L, et al. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys 2000;47:157163.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Gieschen HL, Spiro IJ, Suit HD, et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys 2001;50:127131.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Petersen IA, Haddock MG, Donohue JH, et al. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2002;52:469475.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Bobin JY, Al-Lawati T, Granero LE, et al. Surgical management of retroperitoneal sarcomas associated with external and intraoperative electron beam radiotherapy. Eur J Surg Oncol 2003;29:676681.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Pisters PWT, Ballo MT, Fenstermacher MJ, et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol 2003;21:30923097.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Krempien R, Roeder F, Oertel S, et al. Intraoperative electron-beam therapy for primary and recurrent retroperitoneal soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2006;65:773779.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Stucky CCH, Wasif N, Ashman JB, et al. Excellent local control with preoperative radiation therapy, surgical resection, and intra-operative electron radiation therapy for retroperitoneal sarcoma. J Surg Oncol 2014;109:798803.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Roeder F, Ulrich A, Habl G, et al. Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis. BMC Cancer 2014;14:617.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Pisters PW, Patel SR, Varma DG, et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol 1997;15:34813487.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer 2001;37:10961103.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Cormier JN, Huang X, Xing Y, et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 2004;22:45674574.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 2004;15:16671672.

  • 37.

    Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 2017;18: 812822.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Edmonson JH, Petersen IA, Shives TC, et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. Cancer 2002;94:786792.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Pisters PWT, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol 2002;9: 535542.

  • 40.

    DeLaney TF, Spiro IJ, Suit HD, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003;56:11171127.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Mack LA, Crowe PJ, Yang JL, et al. Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma. Ann Surg Oncol 2005;12:646653.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 2006;24:619625.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Kraybill WG, Harris J, Spiro IJ, et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer 2010;116:46134621.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Mullen JT, Kobayashi W, Wang JJ, et al. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer 2012;118:37583765.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Look Hong NJ, Hornicek FJ, Harmon DC, et al. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer 2013;49:875883.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Tseng WW, Zhou S, To CA, et al. Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. Cancer 2015;121:36593667.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Davis EJ, Chugh R, Zhao L, et al. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. Eur J Cancer 2015;51:17941802.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    US National Library of Medicine. ClinicalTrials.gov. Accessed April 13, 2022. Available at: https://www.clinicaltrials.gov/

  • 49.

    Tierney JF, Mosseri V, Stewart LA, et al. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 1995;72:469475.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350:16471654.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Maki RG. Role of chemotherapy in patients with soft tissue sarcomas. Expert Rev Anticancer Ther 2004;4:229236.

  • 52.

    Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113:573581.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Italiano A, Delva F, Mathoulin-Pelissier S, et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol 2010;21:24362441.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994;12:11371149.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:12381247.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol 2002;25:468473.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 57.

    Woll PJ, van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial [abstract]. J Clin Oncol 2007;25(Suppl):10008.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 58.

    Fakhrai N, Ebm C, Kostler WJ, et al. Intensivierte adjuvante IFADIC Chemotherapie in Kombination mit Radiotherapie versus Radiotherapie alleine für Weichteilsarkome: Langzeit-Verlaufskontrolle einer prospektiven randomisierten Machbarkeitsstudie [Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trial]. Wien Klin Wochenschr 2010;122:614619 [in German].

    • Search Google Scholar
    • Export Citation
  • 59.

    Le Cesne A, Ouali M, Leahy MG, et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol 2014;25:24252432.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003;65(Suppl 2):8084.

  • 61.

    Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1987;23:14771483.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:12081216.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 63.

    Antman KH, Elias A. Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol 1990;17(1 Suppl 2):715.

  • 64.

    Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991;2:307309.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:12761285.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 66.

    Bramwell VHC, Anderson D, Charette ML, et al. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003;2003:CD003293.

    • Search Google Scholar
    • Export Citation
  • 67.

    Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:12691275.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 68.

    Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991;83:926932.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 69.

    Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:15371545.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Reichardt P, Tilgner J, Hohenberger P, et al. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998;16:14381443.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 71.

    Palumbo R, Neumaier C, Cosso M, et al. Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. Eur J Cancer 1999;35:6672.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25:31443150.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Young RJ, Natukunda A, Litière S, et al. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer 2014;50:31783186.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Savina M, Le Cesne A, Blay JY, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med 2017;15:78.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 75.

    Bay JO, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006;119:706711.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007;25:27552763.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer 2007;109:18631869.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    García-Del-Muro X, López-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011;29: 25282533.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 79.

    Seddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017;18:13971410.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Talbot SM, Keohan ML, Hesdorffer M, et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 2003;98:19421946.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 81.

    Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003;98:26932699.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Garcia del Muro X, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005;104:17061712.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 83.

    Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870877.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 84.

    Anderson SE, Keohan ML, D’Adamo DR, et al. A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma 2006;2006:15947.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Kuttesch JF Jr., Krailo MD, Madden T, et al. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children’s Oncology Group study. Pediatr Blood Cancer 2009;53:590593.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Laverdiere C, Kolb EA, Supko JG, et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003;98:832840.

  • 87.

    Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890899.

  • 88.

    Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2005;23:576584.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23:54845492.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27:41884196.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 91.

    Cesne AL, Judson I, Maki R, et al. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer 2013;109: 17171724.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016;34:786793.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 93.

    Le Cesne A, Blay JY, Domont J, et al. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncol 2015;16:312319.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol 2015;16:406416.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Patel S, von Mehren M, Reed DR, et al. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer 2019;125:26102620.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 96.

    Blay JY, Leahy MG, Nguyen BB, et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer 2014;50:11371147.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Le Cesne A, JYB, Cupissol D, et al. Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS) [abstract]. Presented at the 2016 ESMO Congress; October 7–11, 2016; Copenhagen, Denmark.

    • Search Google Scholar
    • Export Citation
  • 98.

    Martin-Broto J, Pousa AL, de Las Peñas R, et al. Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish Group for Research on Sarcoma Study. J Clin Oncol 2016;34:22942302.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 99.

    Schöffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011;12:10451052.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016;387:16291637.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 101.

    Kollár A, Jones RL, Stacchiotti S, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol 2017;56:8892.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:31263132.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    van der Graaf WTA, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:18791886.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Kawai A, Araki N, Hiraga H, et al. A randomized, double-blind, placebo-controlled, phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup. Jpn J Clin Oncol 2016;46:248253.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Toulmonde M, Pulido M, Ray-Coquard I, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol 2019;20:12631272.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Stacchiotti S, Mir O, Le Cesne A, et al. Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. Oncologist 2018;23: 6270.

  • 107.

    Ebata T, Shimoi T, Bun S, et al. Efficacy and safety of pazopanib for recurrent or metastatic solitary fibrous tumor. Oncology 2018;94:340344.

  • 108.

    Coens C, van der Graaf WTA, Blay JY, et al. Health-related quality-of-life results from PALETTE: a randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group global network study (EORTC 62072). Cancer 2015;121:29332941.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Kasper B, Sleijfer S, Litière S, et al. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol 2014;25:719724.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Grünwald V, Karch A, Schuler M, et al. Randomized comparison of pazopanib and doxorubicin as first-line treatment in patients with metastatic soft tissue sarcoma age 60 years or older: Results of a German intergroup study. J Clin Oncol 2020;38:35553564.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Somaiah N, Van Tine BA, Wahlquist AE, et al. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer 2021;127:894904.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 112.

    Berry V, Basson L, Bogart E, et al. REGOSARC: regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis. Cancer 2017;123:22942302.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 113.

    Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2016;17:17321742.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Agulnik M, Schulte B, Robinson S, et al. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. Eur J Cancer 2021;154:201208.

  • 115.

    Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271282.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 116.

    Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731739.

  • 117.

    Merck & Co., Inc. Full Prescribing information: Keytruda (pembrolizumab) injection, for intravenous use. 2022. Accessed March 11, 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s125lbl.pdf

    • Search Google Scholar
    • Export Citation
  • 118.

    Burgess MA, Bolejack V, Van Tine BA, et al. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): final results of SARC028 and biomarker analyses [abstract]. J Clin Oncol 2017;35(Suppl):11008.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 119.

    Florou V, Rosenberg AE, Wieder E, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer 2019;7:213.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Anaya DA, Lev DC, Pollock RE. The role of surgical margin status in retroperitoneal sarcoma. J Surg Oncol 2008;98:607610.

  • 121.

    Bevilacqua RG, Rogatko A, Hajdu SI, et al. Prognostic factors in primary retroperitoneal soft-tissue sarcomas. Arch Surg 1991;126:328334.

  • 122.

    Heslin MJ, Lewis JJ, Nadler E, et al. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol 1997;15:28322839.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228:355365.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 124.

    Bremjit PJ, Jones RL, Chai X, et al. A contemporary large single-institution evaluation of resected retroperitoneal sarcoma. Ann Surg Oncol 2014;21:21502158.

  • 125.

    Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol 2009;27:3137.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 126.

    Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol 2009;27:2430.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 127.

    Ballo MT, Zagars GK, Pollock RE, et al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys 2007;67:158163.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Gronchi A, Casali PG, Fiore M, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer 2004;100:24482455.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 129.

    Stoeckle E, Coindre JM, Bonvalot S, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer 2001;92:359368.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Raut CP, Pisters PWT. Retroperitoneal sarcomas: combined-modality treatment approaches. J Surg Oncol 2006;94:8187.

  • 131.

    Miura JT, Charlson J, Gamblin TC, et al. Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma. Eur J Surg Oncol 2015;41:13861392.

  • 132.

    Thomas DM, O’Sullivan B, Gronchi A. Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. Expert Rev Anticancer Ther 2009;9:11451157.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Mendenhall WM, Zlotecki RA, Hochwald SN, et al. Retroperitoneal soft tissue sarcoma. Cancer 2005;104:669675.

  • 134.

    Windham TC, Pisters PWT. Retroperitoneal sarcomas. Cancer Contr 2005;12:3643.

  • 135.

    Singer S, Corson JM, Demetri GD, et al. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg 1995;221:185195.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 136.

    Mullinax JE, Zager JS, Gonzalez RJ. Current diagnosis and management of retroperitoneal sarcoma. Cancer Contr 2011;18:177187.

  • 137.

    Yoon SS, Chen YL, Kambadakone A, et al. Surgical placement of biologic mesh spacers prior to external beam radiation for retroperitoneal and pelvic tumors. Pract Radiat Oncol 2013;3:199208.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014;15:415423.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2077 2077 2070
PDF Downloads 1427 1427 1420
EPUB Downloads 0 0 0